{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:19:57Z","timestamp":1780463997102,"version":"3.54.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Innovation and Entrepreneurship Training Program for China Medical University Students","award":["202510159035"],"award-info":[{"award-number":["202510159035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05616-8","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:23:47Z","timestamp":1767493427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances of the Role of Dl-3-n-Butylphthalide in the Treatment of Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Hansi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"1","key":"5616_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J et al (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9(1):211","journal-title":"Signal Transduct Target Ther"},{"key":"5616_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041161","author":"M Babi\u0107 Leko","year":"2023","unstructured":"Babi\u0107 Leko M et al (2023) Metals in Alzheimer\u2019s disease. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11041161","journal-title":"Biomedicines"},{"issue":"2","key":"5616_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2009.01.015","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings J et al (2024) Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 10(2):e12465","journal-title":"Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions"},{"key":"5616_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169305","author":"X Morat\u00f3","year":"2022","unstructured":"Morat\u00f3 X et al (2022) Symptomatic and disease-modifying therapy pipeline for Alzheimer\u2019s disease: towards a personalized polypharmacology patient-centered approach. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23169305","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5616_CR5","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1021\/acsptsci.5c00077","volume":"8","author":"S Jain","year":"2025","unstructured":"Jain S et al (2025) Harnessing metabolism to combat neurodegeneration: strategies for reversing age-related cognitive decline. ACS Pharmacol Transl Sci 8(9):2868\u20132886","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"5616_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-024-00908-7","volume":"60","author":"S Jain","year":"2024","unstructured":"Jain S, Chauhan N (2024) Exploring non-canonical targets in Alzheimer\u2019s disease: a departure from the norm. Egypt J Neurol Psychiatr Neurosurg 60(1):135","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"issue":"6","key":"5616_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41593-022-01084-8","volume":"25","author":"JH Lee","year":"2022","unstructured":"Lee JH et al (2022) Faulty autolysosome acidification in Alzheimer\u2019s disease mouse models induces autophagic build-up of A\u03b2 in neurons, yielding senile plaques. Nat Neurosci 25(6):688\u2013701","journal-title":"Nat Neurosci"},{"key":"5616_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101451","volume":"71","author":"R Ullah","year":"2021","unstructured":"Ullah R et al (2021) Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer\u2019s pathology: insights and therapeutic approaches from periphery. Ageing Res Rev 71:101451","journal-title":"Ageing Res Rev"},{"issue":"1","key":"5616_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC et al (2022) ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17(1):72","journal-title":"Mol Neurodegener"},{"issue":"2","key":"5616_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/WCO.0000000000001242","volume":"37","author":"G Nicolas","year":"2024","unstructured":"Nicolas G (2024) Recent advances in Alzheimer disease genetics. Curr Opin Neurol 37(2):154\u2013165","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"5616_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y et al (2023) Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther 8(1):248","journal-title":"Signal Transduct Target Ther"},{"key":"5616_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102161","volume":"93","author":"A Granzotto","year":"2024","unstructured":"Granzotto A, Sensi SL (2024) Once upon a time, the amyloid cascade hypothesis. Ageing Res Rev 93:102161","journal-title":"Ageing Res Rev"},{"issue":"8","key":"5616_CR13","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4103\/1673-5374.332127","volume":"17","author":"AR Roda","year":"2022","unstructured":"Roda AR et al (2022) Amyloid-beta peptide and tau protein crosstalk in Alzheimer\u2019s disease. Neural Regen Res 17(8):1666\u20131674","journal-title":"Neural Regen Res"},{"issue":"9","key":"5616_CR14","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.7150\/ijbs.57078","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H et al (2021) Interaction between A\u03b2 and tau in the pathogenesis of Alzheimer\u2019s disease. Int J Biol Sci 17(9):2181\u20132192","journal-title":"Int J Biol Sci"},{"issue":"3","key":"5616_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s00415-021-10573-y","volume":"269","author":"Y Wei","year":"2022","unstructured":"Wei Y, Liu M, Wang D (2022) The propagation mechanisms of extracellular tau in Alzheimer\u2019s disease. J Neurol 269(3):1164\u20131181","journal-title":"J Neurol"},{"issue":"1","key":"5616_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W et al (2023) Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther 8(1):267","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5616_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11033-023-09021-z","volume":"51","author":"R Dhapola","year":"2024","unstructured":"Dhapola R et al (2024) Oxidative stress in Alzheimer\u2019s disease: current knowledge of signaling pathways and therapeutics. Mol Biol Rep 51(1):48","journal-title":"Mol Biol Rep"},{"key":"5616_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.106413","author":"S Jain","year":"2024","unstructured":"Jain S et al (2024) Unlocking therapeutic potential of siRNA-based drug delivery system for treatment of Alzheimer\u2019s disease. J Drug Deliv Sci Technol. https:\/\/doi.org\/10.1016\/j.jddst.2024.106413","journal-title":"J Drug Deliv Sci Technol"},{"issue":"11","key":"5616_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","volume":"18","author":"S Khan","year":"2020","unstructured":"Khan S, Barve KH, Kumar MS (2020) Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s disease. Curr Neuropharmacol 18(11):1106\u20131125","journal-title":"Curr Neuropharmacol"},{"issue":"000","key":"5616_CR20","first-page":"31","volume":"16","author":"ASA Manap","year":"2024","unstructured":"Manap ASA et al (2024) Alzheimer\u2019s disease: a review on the current trends of the effective diagnosis and therapeutics. Frontiers in Aging Neuroscience 16(000):31","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"9","key":"5616_CR21","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","volume":"29","author":"WK Self","year":"2023","unstructured":"Self WK, Holtzman DM (2023) Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med 29(9):2187\u20132199","journal-title":"Nat Med"},{"issue":"2","key":"5616_CR22","first-page":"199","volume":"30","author":"Q Huang","year":"2023","unstructured":"Huang Q et al (2023) Advance on the clinical research of Alzheimer\u2019s treatment. Chin J Clin Med 30(2):199\u2013208","journal-title":"Chin J Clin Med"},{"issue":"5","key":"5616_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/1871527317666180612125843","volume":"17","author":"S Wang","year":"2018","unstructured":"Wang S et al (2018) Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets 17(5):338\u2013347","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"7","key":"5616_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09909","volume":"8","author":"M Sun","year":"2022","unstructured":"Sun M et al (2022) Long-term L-3-n-butylphthalide pretreatment attenuates ischemic brain injury in mice with permanent distal middle cerebral artery occlusion through the Nrf2 pathway. Heliyon 8(7):e09909","journal-title":"Heliyon"},{"issue":"1","key":"5616_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/1673-5374.343892","volume":"18","author":"C Hu","year":"2023","unstructured":"Hu C et al (2023) DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson\u2019s disease. Neural Regen Res 18(1):194\u2013199","journal-title":"Neural Regen Res"},{"key":"5616_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00137","author":"M Li","year":"2020","unstructured":"Li M et al (2020) Dl-3-n-butylphthalide promotes remyelination and suppresses inflammation by regulating AMPK\/SIRT1 and STAT3\/NF-\u03baB signaling in chronic cerebral hypoperfusion. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2020.00137","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"5616_CR27","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1080\/01616412.2019.1672387","volume":"41","author":"M Gao","year":"2019","unstructured":"Gao M et al (2019) DL-3-n-butylphthalide (NBP) ameliorates cognitive deficits and CaMKII-mediated long-term potentiation impairment in the hippocampus of diabetic db\/db mice. Neurol Res 41(11):1024\u20131033","journal-title":"Neurol Res"},{"issue":"11","key":"5616_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/cns.13952","volume":"28","author":"Q Zhou","year":"2022","unstructured":"Zhou Q et al (2022) Efficacy and safety of 3\u2010n\u2010butylphthalide for the treatment of cognitive impairment: a systematic review and meta\u2010analysis. CNS Neuroscience & Therapeutics 28(11):1706\u20131717","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"S6","key":"5616_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.088925","volume":"20","author":"P Wang","year":"2024","unstructured":"Wang P et al (2024) Efficacy and safety of DL-3-n-butylphthalide in patients with mild cognitive impairment: a multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement 20(S6):e088925","journal-title":"Alzheimers Dement"},{"issue":"01","key":"5616_CR30","first-page":"62","volume":"48","author":"L Ku","year":"2021","unstructured":"Ku L (2021) The effect of butylphthalide in patients with senile dementia. J Int Psychiatry 48(01):62\u201364+69","journal-title":"J Int Psychiatry"},{"issue":"2","key":"5616_CR31","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1124\/dmd.112.049684","volume":"41","author":"X Diao","year":"2013","unstructured":"Diao X et al (2013) Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos 41(2):430\u201344","journal-title":"Drug Metab Dispos"},{"key":"5616_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7232457","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) Role of butylphthalide in immunity and inflammation: butylphthalide may be a potential therapy for anti-inflammation and immunoregulation. Oxid Med Cell Longev 2022:7232457","journal-title":"Oxid Med Cell Longev"},{"key":"5616_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1013933","author":"J Yang","year":"2022","unstructured":"Yang J et al (2022) New insight into neurological degeneration: inflammatory cytokines and blood\u2013brain barrier. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2022.1013933","journal-title":"Front Mol Neurosci"},{"key":"5616_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.620176","author":"Y Chang","year":"2021","unstructured":"Chang Y et al (2021) Dl-3-n-butylphthalide reduces cognitive deficits and alleviates neuropathology in P301S tau transgenic mice. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2021.620176","journal-title":"Front Neurosci"},{"key":"5616_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2024.110969","volume":"212","author":"J Lu","year":"2024","unstructured":"Lu J et al (2024) Dl-3-n-butylphthalide promotes microglial phagocytosis and inhibits microglial inflammation via regulating AGE-RAGE pathway in APP\/PS1 mice. Brain Res Bull 212:110969","journal-title":"Brain Res Bull"},{"issue":"11","key":"5616_CR36","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1089\/ars.2017.7440","volume":"30","author":"C Wang","year":"2019","unstructured":"Wang C et al (2019) Dl-3-n-Butylphthalide inhibits NLRP3 inflammasome and mitigates Alzheimer\u2019s-like pathology via Nrf2-TXNIP-TrX axis. Antioxid Redox Signal 30(11):1411\u20131431","journal-title":"Antioxid Redox Signal"},{"issue":"02","key":"5616_CR37","first-page":"112","volume":"38","author":"Z Sun","year":"2021","unstructured":"Sun Z et al (2021) Effect of butylphthalide on the memory ability of rats with diabetes mellitus and Alzheimer\u2019s disease. Journal of Xinxiang Medical University 38(02):112\u2013117","journal-title":"Journal of Xinxiang Medical University"},{"key":"5616_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neurobiolaging.2015.10.024","volume":"38","author":"C Wang","year":"2016","unstructured":"Wang C et al (2016) Dl-3-n-butylphthalide-induced upregulation of antioxidant defense is involved in the enhancement of cross talk between CREB and Nrf2 in an Alzheimer\u2019s disease mouse model. Neurobiol Aging 38:32\u201346","journal-title":"Neurobiol Aging"},{"issue":"04","key":"5616_CR39","first-page":"405","volume":"49","author":"C Deng","year":"2020","unstructured":"Deng C et al (2020) Effect of dl-3-n-butylphthalide on the expression of BDNF and bFGF in CA1 region of hippocampus of Alzheimer disease rats. Shaanxi Medical Journal 49(04):405\u2013410","journal-title":"Shaanxi Medical Journal"},{"issue":"3","key":"5616_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12640-018-9905-3","volume":"34","author":"H Lei","year":"2018","unstructured":"Lei H et al (2018) L-3-n-butylphthalide regulates proliferation, migration, and differentiation of neural stem cell in vitro and promotes neurogenesis in APP\/PS1 mouse model by regulating BDNF\/TrkB\/CREB\/Akt pathway. Neurotox Res 34(3):477\u2013488","journal-title":"Neurotox Res"},{"key":"5616_CR41","unstructured":"Su L et al (2023) Butylphthalide soft capsule ameliorates learning and memory impairment in Alzheimer\u2019s disease mice model by inhibiting neuronal pyroptosis. J Jinzhou Med Univ 44(01):23\u201327+33"},{"key":"5616_CR42","first-page":"1","volume":"23","author":"L Zhang","year":"2019","unstructured":"Zhang L et al (2019) N-butylphthalide affects cognitive function of APP\/PS1 transgenic mice (Alzheimer’s disease model)&nbsp. Chinese Journal of Tissue Engineering Research 23:1\u20136","journal-title":"Chinese Journal of Tissue Engineering Research"},{"issue":"3","key":"5616_CR43","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s12035-020-02183-y","volume":"58","author":"L Huang","year":"2021","unstructured":"Huang L et al (2021) L-3-n-butylphthalide improves synaptic and dendritic spine plasticity and ameliorates neurite pathology in Alzheimer\u2019s disease mouse model and cultured hippocampal neurons. Mol Neurobiol 58(3):1260\u20131274","journal-title":"Mol Neurobiol"},{"issue":"6","key":"5616_CR44","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1007\/s12035-022-02777-8","volume":"59","author":"B Li","year":"2022","unstructured":"Li B et al (2022) CaMKII\u03b1 signaling is required for the neuroprotective effects of Dl-3-n-butylphthalide in Alzheimer\u2019s disease. Mol Neurobiol 59(6):3370\u20133381","journal-title":"Mol Neurobiol"},{"key":"5616_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.149435","volume":"1849","author":"Y Tian","year":"2025","unstructured":"Tian Y, Li W, Zhang Y (2025) 3-N-butylphthalide alleviate A\u03b2-induced cellular senescence through the CDK2-pRB1-Caspase3 axis. Brain Res 1849:149435","journal-title":"Brain Res"},{"key":"5616_CR46","unstructured":"Guo L et al (2020) Butylphthalide regulates the inflammatory response of BV-2 microglial cells by inducing autophagy. J China Med Univ 49(1):27\u201330"},{"issue":"6","key":"5616_CR47","first-page":"9242","volume":"9","author":"Y Zhou","year":"2016","unstructured":"Zhou Y et al (2016) Dl-3n-butylphthalide protects against the permeability changes of blood brain barrier by influencing tight junctions in Alzheimer\u2019s disease. Int J Clin Exp Med 9(6):9242\u20139251","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"5616_CR48","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1007\/s12031-020-01752-z","volume":"71","author":"B Zhang","year":"2021","unstructured":"Zhang B et al (2021) L-3-n-butylphthalide effectively improves the glymphatic clearance and reduce amyloid-\u03b2 deposition in Alzheimer\u2019s transgenic mice. J Mol Neurosci 71(6):1266\u20131274","journal-title":"J Mol Neurosci"},{"key":"5616_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fnagi.2018.00200","volume":"10","author":"C Lv","year":"2018","unstructured":"Lv C et al (2018) Long-term DL-3-n-butylphthalide treatment alleviates cognitive impairment correlate with improving synaptic plasticity in SAMP8 mice. Front Aging Neurosci 10:200","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"5616_CR50","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3233\/JAD-201381","volume":"80","author":"J Wang","year":"2021","unstructured":"Wang J et al (2021) Donepezil combined with DL-3-n-butylphthalide delays cognitive decline in patients with mild to moderate Alzheimer\u2019s disease: a multicenter, prospective cohort study. J Alzheimers Dis 80(2):673\u2013681","journal-title":"J Alzheimers Dis"},{"issue":"24","key":"5616_CR51","first-page":"29","volume":"17","author":"W Huang","year":"2024","unstructured":"Huang W, Wu Z, Huang X (2024) Effect of donepezil combined with butylphthalide in the treatment of elderly Alzheimer\u2019s disease and its influence on Hcy, CysC and VEGF. Chin J of Clinical Rational Drug Use 17(24):29\u201333","journal-title":"Chin J of Clinical Rational Drug Use"},{"issue":"04","key":"5616_CR52","first-page":"564","volume":"35","author":"H Wang","year":"2024","unstructured":"Wang H et al (2024) Mechanism study of donepezil combined with butylphthalide in the treatment of Alzheimer\u2019s disease based on network pharmacology. Hainan Med J 35(04):564\u2013569","journal-title":"Hainan Med J"},{"issue":"19","key":"5616_CR53","first-page":"135","volume":"7","author":"Y Chen","year":"2023","unstructured":"Chen Y, Guan N (2023) The improvement effect on cognitive function in patients with Alzheimer\u2019s disease through the combined use of butylphthalide soft capsules and donepezil under the nursing intervention of puppet therapy. Modern Medicine and Health Research 7(19):135\u2013137","journal-title":"Modern Medicine and Health Research"},{"issue":"05","key":"5616_CR54","first-page":"529","volume":"34","author":"Z Wang","year":"2022","unstructured":"Wang Z, Deng J (2022) Clinical observation of butylphthalide combined with donepezil in the treatment of Alzheimer\u2019s disease. J Henan Med Coll 34(05):529\u2013532","journal-title":"J Henan Med Coll"},{"issue":"07","key":"5616_CR55","first-page":"139","volume":"28","author":"M Yan","year":"2022","unstructured":"Yan M (2022) Effect of butylphthalein combined with donepezil on cerebrovascular reserve function and serum Hcy levels in Alzheimer\u2019s disease patients. Contemp Med 28(07):139\u2013141","journal-title":"Contemp Med"},{"issue":"09","key":"5616_CR56","first-page":"61","volume":"16","author":"J Chen","year":"2023","unstructured":"Chen J et al (2023) The clinical efficacy of butylphthalide combined with memantine hydrochloride tablets in the treatment of Alzheimer\u2019s disease with cognitive impairment. Chinese Journal of Clinical Rational Drug Use 16(09):61\u201363","journal-title":"Chinese Journal of Clinical Rational Drug Use"},{"issue":"16","key":"5616_CR57","first-page":"93","volume":"21","author":"W Zhao","year":"2021","unstructured":"Zhao W (2021) Clinical study on the treatment of Alzheimer\u2019s disease with memantine combined with butylphthalide. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 21(16):93\u201394","journal-title":"Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine"},{"key":"5616_CR58","unstructured":"Zhao H et al (2019) Effects of DI-3-n-butylphthalide combined with memantine on oxidative stress, endothelial function and cognitive function in Alzheimer\u2019s disease patients. Prog Modern Biomed 19(20):3904\u20133907+3898"},{"issue":"04","key":"5616_CR59","first-page":"59","volume":"37","author":"H Zhang","year":"2014","unstructured":"Zhang H, Liu Y, Zhang J (2014) Clinical study on the effect of Shengui Yizhi Fang combined with butylphthalein on vascular endothelial function in patients with Alzheimer\u2019s disease. Journal of Yunnan University of Chinese 37(04):59\u201361","journal-title":"Journal of Yunnan University of Chinese"},{"issue":"03","key":"5616_CR60","first-page":"84","volume":"17","author":"H Zhang","year":"2015","unstructured":"Zhang H et al (2015) Effect of Shengui Yizhi Fang combined with butylphthalide on expression of endothelial function of patients with Alzheimer\u2019s disease. Journal of Liaoning University of Traditional 17(03):84\u201386","journal-title":"Journal of Liaoning University of Traditional"},{"issue":"4\u20135","key":"5616_CR61","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1023\/A:1025092617651","volume":"23","author":"C Iadecola","year":"2003","unstructured":"Iadecola C (2003) Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer\u2019s dementia. Cell Mol Neurobiol 23(4\u20135):681\u2013689","journal-title":"Cell Mol Neurobiol"},{"issue":"13","key":"5616_CR62","first-page":"3425","volume":"47","author":"H Xiao","year":"2022","unstructured":"Xiao H et al (2022) Research progress on pharmacology of butylphthalide and its derivatives. Zhongguo Zhong Yao Za Zhi 47(13):3425\u20133431","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"1","key":"5616_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01512-w","volume":"28","author":"W Wu","year":"2023","unstructured":"Wu W et al (2023) The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res 28(1):544","journal-title":"Eur J Med Res"},{"issue":"1","key":"5616_CR64","doi-asserted-by":"publisher","first-page":"25741","DOI":"10.1038\/s41598-024-75204-8","volume":"14","author":"KI Avgerinos","year":"2024","unstructured":"Avgerinos KI et al (2024) Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness. Sci Rep 14(1):25741","journal-title":"Sci Rep"},{"issue":"12","key":"5616_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04614-6","volume":"79","author":"Q Aerqin","year":"2022","unstructured":"Aerqin Q et al (2022) Omics-based biomarkers discovery for Alzheimer\u2019s disease. Cell Mol Life Sci 79(12):585","journal-title":"Cell Mol Life Sci"},{"issue":"11","key":"5616_CR66","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","volume":"82","author":"T Hu","year":"2021","unstructured":"Hu T et al (2021) Next-generation sequencing technologies: an overview. Hum Immunol 82(11):801\u2013811","journal-title":"Hum Immunol"},{"issue":"4","key":"5616_CR67","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tig.2023.01.003","volume":"39","author":"K Zhao","year":"2023","unstructured":"Zhao K, Rhee SY (2023) Interpreting omics data with pathway enrichment analysis. Trends Genet 39(4):308\u2013319","journal-title":"Trends Genet"},{"issue":"5","key":"5616_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26642","volume":"10","author":"S He","year":"2024","unstructured":"He S et al (2024) Mechanisms with network pharmacology approach of Ginsenosides in Alzheimer\u2019s disease. Heliyon 10(5):e26642","journal-title":"Heliyon"},{"key":"5616_CR69","doi-asserted-by":"publisher","first-page":"509","DOI":"10.18433\/jpps31788","volume":"24","author":"N Mendoza-Mu\u00f1oz","year":"2021","unstructured":"Mendoza-Mu\u00f1oz N et al (2021) Solid lipid nanoparticles: an approach to improve oral drug delivery. J Pharm Pharm Sci 24:509\u2013532","journal-title":"J Pharm Pharm Sci"},{"issue":"14","key":"5616_CR70","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.2174\/1389200221666200719003304","volume":"21","author":"J Ahmad","year":"2020","unstructured":"Ahmad J et al (2020) Nanostructured lipid carriers (NLCs): nose-to-brain delivery and theranostic application. Curr Drug Metab 21(14):1136\u20131143","journal-title":"Curr Drug Metab"},{"key":"5616_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112296","author":"D Nunes","year":"2022","unstructured":"Nunes D, Loureiro JA, Pereira MC (2022) Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer\u2019s drugs. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14112296","journal-title":"Pharmaceutics"},{"issue":"37","key":"5616_CR72","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.2174\/0113816128275385231027054743","volume":"29","author":"L Kumar","year":"2023","unstructured":"Kumar L et al (2023) Poly(lactic-co-glycolic) acid (PLGA) nanoparticles and transdermal drug delivery: an overview. Curr Pharm Des 29(37):2940\u20132953","journal-title":"Curr Pharm Des"},{"issue":"1","key":"5616_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02511-7","volume":"22","author":"R Moreira","year":"2024","unstructured":"Moreira R et al (2024) Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands. J Nanobiotechnology 22(1):260","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"5616_CR74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/med.10008","volume":"22","author":"H Li","year":"2002","unstructured":"Li H, Qian ZM (2002) Transferrin\/transferrin receptor-mediated drug delivery. Med Res Rev 22(3):225\u2013250","journal-title":"Med Res Rev"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05616-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05616-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05616-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T03:02:50Z","timestamp":1767495770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05616-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5616"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05616-8","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not involve any materials or ethical issues related to human or animal subjects, so no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This article does not involve any materials or ethical issues related to human or animal subjects, so the consent is not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"340"}}